ID   ABC-14
AC   CVCL_A1EF
DR   Cosmic; 2843080
DR   Wikidata; Q102113498
RX   PubMed=31374369;
CC   Population: Japanese.
CC   Characteristics: Sensitive to crizotinib and resistant to alectinib.
CC   Sequence variation: Gene fusion; HGNC; HGNC:427; ALK + HGNC; HGNC:1316; EML4; Name(s)=EML4-ALK (PubMed=31374369).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_A1EG ! ABC-17
SX   Male
AG   51Y
CA   Cancer cell line
DT   Created: 29-10-20; Last updated: 19-12-24; Version: 6
//
RX   PubMed=31374369; DOI=10.1016/j.jtho.2019.07.017;
RA   Makimoto G., Ohashi K., Tomida S., Nishii K., Matsubara T.,
RA   Kayatani H., Higo H., Ninomiya K., Sato A., Watanabe H., Kano H.,
RA   Ninomiya T., Kubo T., Rai K., Ichihara E., Hotta K., Tabata M.,
RA   Toyooka S., Takata M., Maeda Y., Kiura K.;
RT   "Rapid acquisition of alectinib resistance in ALK-positive lung cancer
RT   with high tumor mutation burden.";
RL   J. Thorac. Oncol. 14:2009-2018(2019).
//